HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,830.00
+30.00 (0.44%)
Nov 17, 2026, 3:30 PM KST

HLB Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2019FY 2018FY 2017
Period Ending
Sep '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Operating Revenue
253,848205,582137,08236,10020,54115,558
Other Revenue
-0-0----
253,848205,582137,08236,10020,54115,558
Revenue Growth
44.85%49.97%279.73%75.75%32.03%-
Cost of Revenue
136,72399,16550,55618,05816,07512,797
Gross Profit
117,125106,41686,52618,0424,4652,760
Selling, General & Admin
106,78799,40280,19813,6727,2813,417
Research & Development
4,6633,3372,4511,8702,4742,736
Amortization of Goodwill & Intangibles
1,6051,4771,45069.4959.69117.71
Other Operating Expenses
298.41427.09378.08197.98246.97155.02
Operating Expenses
114,441105,35385,05216,60110,2926,613
Operating Income
2,6841,0641,4741,441-5,826-3,853
Interest Expense
-733.78-738.08-621.14-1,192-859.58-2,107
Interest & Investment Income
574.89654.91429.9436.96392.45531.35
Earnings From Equity Investments
-763.682,324-1,121---
Currency Exchange Gain (Loss)
0.76-0.54-3.961.79-5.17-76.26
Other Non Operating Income (Expenses)
1,6541,394-3,184-90.42447.16828.7
EBT Excluding Unusual Items
3,4154,699-3,026196.89-5,851-4,676
Gain (Loss) on Sale of Investments
266.23266.42-120.89164.96-332.17
Gain (Loss) on Sale of Assets
-22.0153.1216,406-2.08-31.53-45.09
Asset Writedown
-32.67-32.67-12,215-438.73--509.63
Pretax Income
3,6274,9861,166-123.03-5,718-5,563
Income Tax Expense
252.33414.02-854.13-595.691,342-116.36
Net Income
3,3754,5722,020472.66-7,060-5,447
Net Income to Common
3,3754,5722,020472.66-7,060-5,447
Net Income Growth
-25.04%126.35%327.33%---
Shares Outstanding (Basic)
333232141412
Shares Outstanding (Diluted)
343332141412
Shares Change
6.01%2.25%130.84%2.30%13.08%-
EPS (Basic)
102.17140.8663.7234.13-521.49-455.00
EPS (Diluted)
100.36140.0063.0034.13-521.49-455.00
EPS Growth
-29.10%122.22%84.58%---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2019FY 2018FY 2017
Period Ending
Sep '26 Dec '25 Dec '24 Dec '19 Dec '18 Dec '17
Free Cash Flow
-7,514-6,6424,042-43.8-2,872-3,020
Free Cash Flow Per Share
-223.16-203.19126.44-3.16-212.19-252.31
Gross Margin
46.14%51.76%63.12%49.98%21.74%17.74%
Operating Margin
1.06%0.52%1.07%3.99%-28.37%-24.77%
Profit Margin
1.33%2.22%1.47%1.31%-34.37%-35.01%
Free Cash Flow Margin
-2.96%-3.23%2.95%-0.12%-13.98%-19.41%
EBITDA
7,4965,1766,5633,081-4,684-2,798
EBITDA Margin
2.95%2.52%4.79%8.53%-22.80%-17.98%
D&A For EBITDA
4,8124,1125,0891,6401,1431,055
EBIT
2,6841,0641,4741,441-5,826-3,853
EBIT Margin
1.06%0.52%1.07%3.99%-28.36%-24.77%
Effective Tax Rate
6.96%8.30%----
Advertising Expenses
-4,9323,92963.2781.1898.91